Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HER-2 Positive Breast Cancer × Breast × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2467 Triple Negative Breast Neoplasms 351 Neoplasm Metastasis 144 Breast Neoplasms, Male 97 Neoplasms 91 Carcinoma, Intraductal, Noninfiltrating 63 Ovarian Neoplasms 61 Carcinoma, Non-Small-Cell Lung 58 Lung Neoplasms 55 Brain Neoplasms 55 Breast Carcinoma In Situ 43 Inflammatory Breast Neoplasms 42 Colorectal Neoplasms 41 Advanced Breast Cancer 40 Prostatic Neoplasms 36 Pancreatic Neoplasms 34 Melanoma 32 Stomach Neoplasms 27 HER2-positive Breast Cancer 26 Sarcoma 24 Head and Neck Neoplasms 22 Endometrial Neoplasms 22 Uterine Cervical Neoplasms 20 Recurrence 20 Colonic Neoplasms 19 Multiple Myeloma 18 Carcinoma, Ovarian Epithelial 18 Carcinoma, Renal Cell 17 Carcinoma, Ductal, Breast 17 Esophageal Neoplasms 16

Interventions

liposomal doxorubicin 1 Trastuzumab 1 Metformin 1 Doxorubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02488564 2025-02-03

met-HEReMYTA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed

HER-2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡